Table 4.

Associations between statin use and risk of estrogen receptor–positive or –negative breast cancer

Controls (n = 877)ER+ ductal cases (n = 727)ER− ductal cases (n = 149)ER+ lobular cases (n = 980)
N (%)N (%)OR (95% CI)N (%)OR (95% CI)N (%)OR (95% CI)
Never use674 (77%)541 (74%)1.00 (reference)114 (77%)1.00 (reference)741 (76%)1.00 (reference)
Current use170 (19%)152 (21%)1.17 (0.90–1.51)27 (18%)1.00 (0.63–1.60)208 (21%)1.24 (0.98–1.57)
 6 months–<5 years91 (10%)62 (9%)0.86 (0.60–1.22)13 (9%)0.86 (0.46–1.61)104 (11%)1.12 (0.82–1.53)
 5 years–<10 years47 (5%)45 (6%)1.28 (0.83–1.98)8 (5%)1.08 (0.49–2.37)45 (5%)0.99 (0.64–1.53)
 ≥10 years31 (4%)44 (6%)1.97 (1.21–3.20)6 (4%)1.33 (0.53–3.31)58 (6%)2.00 (1.26–3.17)
PtrendP = 0.035P = 0.740P = 0.023

NOTE: OR adjusted for reference year, reference age, county of residence, and hormone therapy use. Bold values signify statistically significant estimates (P value <0.05).